Meeting
2014 ASCO Annual Meeting
One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.
Authors
James E. Signorovitch
Analysis Group, Inc., Boston, MA
James E. Signorovitch , Eric Qiong Wu , Keith A. Betts , William M. Reichmann , Darren Thomason , Philip J Galebach , Lei Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00471497
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7072)
DOI
10.1200/jco.2014.32.15_suppl.7072
Abstract #
7072
Poster Bd #
357
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.
First Author: Giuseppe Saglio
Poster
2013 ASCO Annual Meeting
Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update.
First Author: Richard A. Larson
Poster
2012 ASCO Annual Meeting
Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u).
First Author: Hagop Kantarjian
Poster
2011 ASCO Annual Meeting
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.
First Author: H. Kantarjian